The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

REMS requires patients to administer Spravato at a clinic in the presence of a physician. “We probably know more about the ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

Spravato is taken by the user under the supervision of a healthcare provider in a clinic. Because reported side-effects include temporary nausea, vomiting, and tiredness, healthcare supervisors ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...